{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:39Z","timestamp":1792784979002,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Romark inc"},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Quiescent cancer cells in malignant tumors can withstand cell-cycle active treatment and cause cancer spread and recurrence. Three-dimensional (3D) cancer cell models have led to the identification of oxidative phosphorylation (OXPHOS) as a context-dependent vulnerability. The limited treatment options for advanced hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) metastatic to the liver include the multikinase inhibitors sorafenib and regorafenib. Off-target effects of sorafenib and regorafenib are related to OXPHOS inhibition; however the importance of this feature to the effect on tumor cells has not been investigated in 3D models. We began by assessing global transcriptional responses in monolayer cell cultures, then moved on to multicellular tumor spheroids (MCTS) and tumoroids generated from a CRC patient. Cells were treated with chemotherapeutics, kinase inhibitors, and the OXPHOS inhibitors. Cells grown in 3D cultures were sensitive to the OXPHOS inhibitor nitazoxanide, sorafenib, and regorafenib and resistant to other multikinase inhibitors and chemotherapeutic drugs. Furthermore, nitazoxanide and sorafenib reduced viability, regrowth potential and inhibited mitochondrial membrane potential in an additive manner at clinically relevant concentrations. This study demonstrates that the OXPHOS inhibition caused by sorafenib and regorafenib parallels 3D activity and can be further investigated for new combination strategies.<\/jats:p>","DOI":"10.1038\/s41598-022-12519-4","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T07:04:05Z","timestamp":1653635045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Frida","family":"Ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Selvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Rudfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Senkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nygren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Jarvius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e5rten","family":"Frykn\u00e4s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"12519_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG vanderHeiden","year":"2009","unstructured":"vanderHeiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect. The metabolic requirements of cell proliferation. Science 324, 1029\u20131033 (2009).","journal-title":"Science"},{"key":"12519_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature13110","volume":"508","author":"K Birsoy","year":"2014","unstructured":"Birsoy, K. et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508, 108\u2013112 (2014).","journal-title":"Nature"},{"key":"12519_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1158\/1535-7163.MCT-12-0002","volume":"11","author":"Y-T Yo","year":"2012","unstructured":"Yo, Y.-T. et al. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol. Cancer Ther. 11, 1703\u20131712 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"12519_CR4","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1158\/0008-5472.CAN-15-0491","volume":"75","author":"A Viale","year":"2015","unstructured":"Viale, A., Corti, D. & Draetta, G. F. Tumors and mitochondrial respiration: A neglected connection. Can. Res. 75, 3687\u20133691 (2015).","journal-title":"Can. Res."},{"key":"12519_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0076-6879(04)81023-1","volume":"381","author":"P Vaupel","year":"2004","unstructured":"Vaupel, P., Mayer, A. & H\u00f6ckel, M. Tumor hypoxia and malignant progression. Methods Enzymol. 381, 335\u2013354. https:\/\/doi.org\/10.1016\/S0076-6879(04)81023-1 (2004).","journal-title":"Methods Enzymol."},{"key":"12519_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159675","volume":"11","author":"JE Ippolito","year":"2016","unstructured":"Ippolito, J. E. et al. Extracellular pH modulates neuroendocrine prostate cancer cell metabolism and susceptibility to the mitochondrial inhibitor niclosamide. PLoS ONE 11, e0159675 (2016).","journal-title":"PLoS ONE"},{"key":"12519_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.trecan.2016.10.009","volume":"2","author":"X Zhang","year":"2016","unstructured":"Zhang, X. et al. Eradicating quiescent tumor cells by targeting mitochondrial bioenergetics. Trends Cancer 2, 657\u2013663 (2016).","journal-title":"Trends Cancer"},{"key":"12519_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/ijc.32616","volume":"146","author":"V Sica","year":"2020","unstructured":"Sica, V., Bravo-San Pedro, J. M., Stoll, G. & Kroemer, G. Oxidative phosphorylation as a potential therapeutic target for cancer therapy. Int. J. Cancer 146, 10\u201317 (2020).","journal-title":"Int. J. Cancer"},{"issue":"240","key":"12519_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.2451290","volume":"1979","author":"RM Sutherland","year":"1988","unstructured":"Sutherland, R. M. Cell and environment interactions in tumor microregions: The multicell spheroid model. Science 1979(240), 177\u2013184 (1988).","journal-title":"Science"},{"key":"12519_CR10","doi-asserted-by":"publisher","first-page":"19103","DOI":"10.1038\/srep19103","volume":"6","author":"M Zanoni","year":"2016","unstructured":"Zanoni, M. et al. 3D tumor spheroid models for in vitro therapeutic screening: A systematic approach to enhance the biological relevance of data obtained. Sci. Rep. 6, 19103 (2016).","journal-title":"Sci. Rep."},{"key":"12519_CR11","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.yexcr.2012.03.026","volume":"318","author":"H Karlsson","year":"2012","unstructured":"Karlsson, H., Frykn\u00e4s, M., Larsson, R. & Nygren, P. Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp. Cell Res. 318, 1577\u20131585 (2012).","journal-title":"Exp. Cell Res."},{"key":"12519_CR12","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1158\/1535-7163.MCT-14-0792","volume":"14","author":"W Senkowski","year":"2015","unstructured":"Senkowski, W. et al. Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer. Mol. Cancer Ther. 14, 1504\u20131516 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"12519_CR13","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4438","volume":"23","author":"L Broutier","year":"2017","unstructured":"Broutier, L. et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat. Med. 23, 1424\u20131435 (2017).","journal-title":"Nat. Med."},{"key":"12519_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molmed.2017.02.007","volume":"23","author":"D Dutta","year":"2017","unstructured":"Dutta, D., Heo, I. & Clevers, H. Disease modeling in stem cell-derived 3D organoid systems. Trends Mol. Med. 23, 393\u2013410 (2017).","journal-title":"Trends Mol. Med."},{"issue":"359","key":"12519_CR15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"1979","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 1979(359), 920\u2013926 (2018).","journal-title":"Science"},{"key":"12519_CR16","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1038\/ncomms4295","volume":"5","author":"X Zhang","year":"2014","unstructured":"Zhang, X. et al. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat. Commun. 5, 3295 (2014).","journal-title":"Nat. Commun."},{"key":"12519_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yexcr.2014.01.017","volume":"323","author":"C Wenzel","year":"2014","unstructured":"Wenzel, C. et al. 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp. Cell Res. 323, 131\u2013143 (2014).","journal-title":"Exp. Cell Res."},{"key":"12519_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074538","volume":"8","author":"Y-C Wang","year":"2013","unstructured":"Wang, Y.-C. et al. Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells. PLoS ONE 8, e74538 (2013).","journal-title":"PLoS ONE"},{"key":"12519_CR19","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1073\/pnas.1505979112","volume":"112","author":"A Rotem","year":"2015","unstructured":"Rotem, A. et al. Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. Proc. Natl. Acad. Sci. 112, 5708\u20135713 (2015).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"12519_CR20","doi-asserted-by":"publisher","first-page":"17530","DOI":"10.1074\/jbc.M112.359638","volume":"287","author":"BD Fonseca","year":"2012","unstructured":"Fonseca, B. D. et al. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J. Biol. Chem. 287, 17530\u201317545 (2012).","journal-title":"J. Biol. Chem."},{"key":"12519_CR21","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24, 1036\u20131046 (2018).","journal-title":"Nat. Med."},{"key":"12519_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.tox.2014.11.002","volume":"327","author":"Z Weng","year":"2015","unstructured":"Weng, Z. et al. Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis. Toxicology 327, 10\u201321 (2015).","journal-title":"Toxicology"},{"key":"12519_CR23","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s00204-016-1918-1","volume":"91","author":"J Zhang","year":"2017","unstructured":"Zhang, J. et al. Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria. Arch. Toxicol. 91, 2921\u20132938 (2017).","journal-title":"Arch. Toxicol."},{"key":"12519_CR24","doi-asserted-by":"publisher","first-page":"15105","DOI":"10.1074\/jbc.M117.783175","volume":"292","author":"C Zhang","year":"2017","unstructured":"Zhang, C. et al. Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1\u2013Parkin pathway and modulate cellular drug response. J. Biol. Chem. 292, 15105\u201315120 (2017).","journal-title":"J. Biol. Chem."},{"key":"12519_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.cmet.2020.04.011","volume":"31","author":"C Jian","year":"2020","unstructured":"Jian, C. et al. Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis. Cell Metab. 31, 892-908.e11 (2020).","journal-title":"Cell Metab."},{"key":"12519_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejphar.2011.08.038","volume":"670","author":"L Fiume","year":"2011","unstructured":"Fiume, L., Manerba, M., Vettraino, M. & di Stefano, G. Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells. Eur. J. Pharmacol. 670, 39\u201343 (2011).","journal-title":"Eur. J. Pharmacol."},{"key":"12519_CR27","unstructured":"HMS LINCS Database\u2014HMS LINCS Project. https:\/\/lincs.hms.harvard.edu\/db\/ (2020)."},{"key":"12519_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/toxsci\/kfn157","volume":"106","author":"Y Will","year":"2008","unstructured":"Will, Y. et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 106, 153\u2013161 (2008).","journal-title":"Toxicol. Sci."},{"key":"12519_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/toxsci\/kfm052","volume":"97","author":"LD Marroquin","year":"2007","unstructured":"Marroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D. & Will, Y. Circumventing the Crabtree effect: Replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97, 539\u2013547 (2007).","journal-title":"Toxicol. Sci."},{"key":"12519_CR30","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.chembiol.2016.09.013","volume":"23","author":"W Senkowski","year":"2016","unstructured":"Senkowski, W. et al. Large-scale gene expression profiling platform for identification of context-dependent drug responses in multicellular tumor spheroids. Cell Chem. Biol. 23, 1428\u20131438 (2016).","journal-title":"Cell Chem. Biol."},{"key":"12519_CR31","first-page":"349","volume":"34","author":"A Stockis","year":"1996","unstructured":"Stockis, A. et al. Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers. Int J. Clin. Pharmacol. Ther. 34, 349 (1996).","journal-title":"Int J. Clin. Pharmacol. Ther."},{"key":"12519_CR32","unstructured":"Prichard, M. N. & Aseltine, K. R. MacSynergyTM II. (1993) (online)."},{"key":"12519_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cmet.2014.12.003","volume":"21","author":"AS Tan","year":"2015","unstructured":"Tan, A. S. et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 21, 81\u201394 (2015).","journal-title":"Cell Metab."},{"key":"12519_CR34","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.7554\/eLife.02242","volume":"3","author":"WW Wheaton","year":"2014","unstructured":"Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 3, 2242 (2014).","journal-title":"Elife"},{"key":"12519_CR35","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/cam4.112","volume":"2","author":"P Ellinghaus","year":"2013","unstructured":"Ellinghaus, P. et al. BAY 87\u20132243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med. 2, 611\u2013624 (2013).","journal-title":"Cancer Med."},{"key":"12519_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2019.01.005","author":"L Zhang","year":"2019","unstructured":"Zhang, L., Zhang, J., Ye, Z., Townsend, D. M. & Tew, K. D. Pharmacology of ME-344, a novel cytotoxic isoflavone. Adv. Cancer Res. https:\/\/doi.org\/10.1016\/bs.acr.2019.01.005 (2019).","journal-title":"Adv. Cancer Res."},{"key":"12519_CR37","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1747-0285.2011.01170.x","volume":"78","author":"W Fayad","year":"2011","unstructured":"Fayad, W. et al. Identification of agents that induce apoptosis of multicellular tumour spheroids: Enrichment for mitotic inhibitors with hydrophobic properties. Chem. Biol. Drug Des. 78, 547\u2013557 (2011).","journal-title":"Chem. Biol. Drug Des."},{"key":"12519_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.yrtph.2007.03.006","volume":"48","author":"E Colman","year":"2007","unstructured":"Colman, E. Dinitrophenol and obesity: An early twentieth-century regulatory dilemma. Regul. Toxicol. Pharmacol. 48, 115\u2013117 (2007).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"12519_CR39","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2105\/AJPH.24.10.1045","volume":"24","author":"ML Tainter","year":"1934","unstructured":"Tainter, M. L., Cutting, W. C. & Stockton, A. B. Use of dinitrophenol in nutritional disorders. Am. J. Public Health Nations Health 24, 1045 (1934).","journal-title":"Am. J. Public Health Nations Health"},{"key":"12519_CR40","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2307\/4575357","volume":"34","author":"RG Perkins","year":"1919","unstructured":"Perkins, R. G. A Study of the Munitions intoxications in France. Public Health Rep. (1896-1970) 34, 2335 (1919).","journal-title":"Public Health Rep. (1896-1970)"},{"key":"12519_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000449000","volume":"91","author":"T Kuzuya","year":"2016","unstructured":"Kuzuya, T. et al. Fever within 2 weeks of sorafenib therapy predicts favorable treatment efficacy in patients with advanced hepatocellular carcinoma. Oncology 91, 261\u2013266 (2016).","journal-title":"Oncology"},{"key":"12519_CR42","doi-asserted-by":"publisher","first-page":"46691","DOI":"10.18632\/oncotarget.17358","volume":"8","author":"C Chen","year":"2017","unstructured":"Chen, C. & Lou, T. Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget 8, 46691\u201346703 (2017).","journal-title":"Oncotarget"},{"key":"12519_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.20517\/2394-5079.2018.27","volume":"4","author":"C-A Lin","year":"2018","unstructured":"Lin, C.-A., Chang, L.-L., Zhu, H., He, Q.-J. & Yang, B. Hypoxic microenvironment and hepatocellular carcinoma treatment. Hepatoma Res. 4, 26 (2018).","journal-title":"Hepatoma Res."},{"key":"12519_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.21037\/atm-21-4222","volume":"10","author":"Q Chu","year":"2022","unstructured":"Chu, Q., Gu, X., Zheng, Q. & Zhu, H. Regulatory mechanism of HIF-1\u03b1 and its role in liver diseases: A narrative review. Ann. Transl. Med. 10, 109 (2022).","journal-title":"Ann. Transl. Med."},{"key":"12519_CR45","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.2174\/1568009622666220330151725","volume":"22","author":"Y Tian","year":"2022","unstructured":"Tian, Y. et al. Molecular mechanisms of resistance to tyrosine kinase inhibitors associated with hepatocellular carcinoma. Curr. Cancer Drug Targets 22, 1358 (2022).","journal-title":"Curr. Cancer Drug Targets"},{"key":"12519_CR46","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/jpm12030436","volume":"12","author":"E Kotsifa","year":"2022","unstructured":"Kotsifa, E. et al. Transarterial chemoembolization for hepatocellular carcinoma: Why, when, how?. J. Pers. Med. 12, 436 (2022).","journal-title":"J. Pers. Med."},{"key":"12519_CR47","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4161\/auto.5.8.9996","volume":"5","author":"J Song","year":"2009","unstructured":"Song, J. et al. Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy 5, 1131\u20131144 (2009).","journal-title":"Autophagy"},{"key":"12519_CR48","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1415","author":"W Qiu","year":"2012","unstructured":"Qiu, W. Emerging role of autophagy during ischemia-hypoxia and reperfusion in hepatocellular carcinoma. Int. J. Oncol. https:\/\/doi.org\/10.3892\/ijo.2012.1415 (2012).","journal-title":"Int. J. Oncol."},{"key":"12519_CR49","doi-asserted-by":"publisher","first-page":"12452","DOI":"10.18632\/aging.102582","volume":"11","author":"J Bai","year":"2019","unstructured":"Bai, J. et al. Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib. Aging 11, 12452\u201312475 (2019).","journal-title":"Aging"},{"key":"12519_CR50","doi-asserted-by":"crossref","unstructured":"Stockis, A., Allemon, A.-M., de Bruyn, S. & Gengler, C. Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. Int. Journal of Clinical Pharmacology and Therapeutics 40, 213\u2013220 (2002).","DOI":"10.5414\/CPP40213"},{"key":"12519_CR51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"J-F Rossignol","year":"2014","unstructured":"Rossignol, J.-F. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res. 110, 94\u2013103 (2014).","journal-title":"Antiviral Res."},{"key":"12519_CR52","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1021\/ml200157f","volume":"2","author":"LPS de Carvalho","year":"2011","unstructured":"de Carvalho, L. P. S., Darby, C. M., Rhee, K. Y. & Nathan, C. Nitazoxanide disrupts membrane potential and intrabacterial pH homeostasis of Mycobacterium tuberculosis. ACS Med. Chem. Lett. 2, 849\u2013854 (2011).","journal-title":"ACS Med. Chem. Lett."},{"key":"12519_CR53","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1053\/j.gastro.2017.02.039","volume":"152","author":"B Chen","year":"2017","unstructured":"Chen, B. et al. Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells in vitro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology 152, 2022\u20132036 (2017).","journal-title":"Gastroenterology"},{"key":"12519_CR54","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/2211068215598117","volume":"21","author":"K Blom","year":"2016","unstructured":"Blom, K., Nygren, P., Alvarsson, J., Larsson, R. & Andersson, C. R. Ex vivo assessment of drug activity in patient tumor cells as a basis for tailored cancer therapy. J. Lab. Autom. 21, 178\u2013187 (2016).","journal-title":"J. Lab. Autom."},{"key":"12519_CR55","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/nprot.2008.114","volume":"3","author":"E Lindhagen","year":"2008","unstructured":"Lindhagen, E., Nygren, P. & Larsson, R. The fluorometric microculture cytotoxicity assay. Nat. Protoc. 3, 1364\u20131369 (2008).","journal-title":"Nat. Protoc."},{"key":"12519_CR56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jmoldx.2020.02.009","volume":"22","author":"LI Kroeze","year":"2020","unstructured":"Kroeze, L. I. et al. Evaluation of a hybrid capture-based pan-cancer panel for analysis of treatment stratifying oncogenic aberrations and processes. J. Mol. Diagn. 22, 757\u2013769 (2020).","journal-title":"J. Mol. Diagn."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12519-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12519-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12519-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:06:27Z","timestamp":1669331187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12519-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["12519"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-12519-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"assertion":[{"value":"16 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MF has received an unconditional grant from Romark Inc. CB is employed by Romark Inc. FE, KB, TS, JR, CA, WS, PN and RL do not have any competing interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8943"}}